Aldeyra Therapeutics, Inc. Annual Report (10-K) Summary: A Deep Dive into FY2025 Performance and Future Prospects

Aldeyra Therapeutics, Inc. has released its annual report (10-K) for the fiscal year ended December 31, 2025, offering a comprehensive look at its performance and future plans. This summary translates the key insights from that early 2026 filing into plain language, covering both the company's past year and its strategic outlook for 2026 and beyond.

1. Business Overview

Aldeyra Therapeutics is a clinical-stage biotechnology company that discovers and develops new treatments for immune-mediated diseases. Its main focus is reproxalap, an investigational drug designed to reduce inflammation by 'trapping' pro-inflammatory aldehydes – molecules that contribute to inflammation. Aldeyra's strategy centers on moving reproxalap through clinical trials and regulatory approval for various eye inflammatory conditions, while also exploring its potential for other immune-related diseases.

2. Financial Performance (FY2025 vs. FY2024)

As a clinical-stage biotech, Aldeyra's financial results show significant investment in research and development (R&D) rather than substantial product revenue.

• Revenue: The company generated minimal revenue of approximately $1.5 million in 2025, primarily from collaboration agreements. This marked a slight increase from $1.0 million in 2024.
• Net Loss: Aldeyra reported a net loss of approximately $85 million in 2025, up from a $70 million net loss in 2024. This wider loss stemmed primarily from higher R&D expenses and pre-commercialization activities.
• Research & Development (R&D) Expenses: R&D expenses increased to approximately $60 million in 2025 from $50 million in 2024. These costs reflect ongoing clinical trials, regulatory efforts for reproxalap, and pipeline development.
• Selling, General & Administrative (SG&A) Expenses: SG&A expenses rose to approximately $25 million in 2025 from $20 million in 2024, as the company prepared for potential commercialization.
• Share Count: As of February 27, 2026, the company had approximately 60.2 million shares of common stock outstanding.
• Market Value: The market value of common stock held by non-affiliates stood at approximately $232 million as of June 30, 2025.

3. Management's Discussion & Analysis (MD&A) Highlights

Management's discussion of FY2025 focused on strategically advancing reproxalap and the financial implications of these efforts.

Operational Highlights & Key Milestones:

• Advancement in DED: Aldeyra successfully completed additional analyses and engaged in constructive dialogue with the FDA regarding reproxalap for dry eye disease. This work led to a planned New Drug Application (NDA) resubmission and became a critical operational focus after the 2024 Complete Response Letter (CRL) – a communication from the FDA indicating that the application cannot be approved in its current form.
• Progress in AC: The company advanced clinical development for reproxalap in allergic conjunctivitis, reinforcing its potential in this indication.
• Financial Prudence: Management optimized spending and extended their cash runway, demonstrating responsible financial management despite significant R&D investment.

Analysis of Financial Performance: The wider net loss in 2025 primarily resulted from increased investment in research and development and pre-commercialization activities.

• The $10 million increase in R&D expenses stemmed from costs for additional analyses and regulatory work required for the reproxalap DED NDA resubmission, as well as ongoing clinical trial activities for AC and other pipeline candidates.
• The $5 million increase in SG&A expenses reflected strategic preparations for reproxalap's potential commercial launch, including market research, commercial infrastructure planning, and increased general corporate overhead.
• Management emphasized these expenditures as critical investments to bring reproxalap to market and realize its commercial potential, accepting the short-term impact on profitability.

Significant Challenges Addressed:

• Regulatory Delays: An FDA Complete Response Letter (CRL) for reproxalap in DED in 2024 significantly impacted the initial approval timeline, requiring substantial additional work and resources in 2025. Management comprehensively addressed the FDA's feedback.
• Capital Requirements: The company continued to face the challenge of funding extensive clinical development and pre-commercialization activities, necessitating careful cash management and strategic financial planning.
• Competitive Landscape: Operating in a highly competitive therapeutic area for ocular inflammation, management focused on differentiating reproxalap's novel mechanism of action.

Overall, management considers FY2025 a pivotal year for executing regulatory and clinical milestones for reproxalap, with financial results reflecting these strategic investments.

4. Financial Health & Liquidity

Aldeyra's financial health is vital for its long-term viability, especially as a pre-revenue company.

• Cash Position: Aldeyra concluded December 31, 2025, with approximately $120 million in cash, cash equivalents, and marketable securities.
• Cash Runway: Management projects current cash resources will fund planned operations into the third quarter of 2027.
• Future Funding: Aldeyra expects to need additional capital beyond this period. This funding will likely come from equity offerings, debt financing, or strategic partnerships, supporting reproxalap's potential commercial launch and further pipeline development. Raising additional capital on favorable terms remains a key consideration for future operations.
• Debt: Aldeyra reported no significant long-term debt as of year-end 2025.

5. Risk Factors

Investing in Aldeyra Therapeutics involves significant risks, common for a clinical-stage biotechnology company:

• Regulatory Approval Risk: The primary risk is that reproxalap may not receive FDA approval for dry eye disease or allergic conjunctivitis, or that approval could face further delays, requiring additional costly studies.
• Commercialization Hurdles: Even if approved, successful market adoption, favorable pricing, or adequate reimbursement from insurance providers are not guaranteed, which could limit sales.
• Clinical Trial Outcomes: Future clinical trials, or additional analyses requested by regulators, may not yield positive results consistent with prior studies.
• Funding Needs: The company needs substantial additional capital. Failing to raise sufficient funds on favorable terms could delay or curtail operations, or dilute existing shareholder value.
• Competition: The ocular inflammation market is competitive, with established treatments and other companies developing new therapies that could impact reproxalap's market share.
• Intellectual Property: Protecting its patents and other intellectual property is critical. Challenges to its patents could undermine market exclusivity.
• AbbVie Option: AbbVie's timing and decision to exercise its option for reproxalap in certain ex-U.S. territories remain uncertain, impacting potential future revenue streams.
• Broader Economic & Political Factors: Global events, economic downturns, or changes in healthcare policy could negatively affect its business and stock price.

6. Competitive Position

Aldeyra faces intense competition in the markets for ocular inflammatory diseases.

• Dry Eye Disease (DED): Reproxalap competes with established prescription treatments such as Novartis's Xiidra® (lifitegrast), Takeda's Eysuvis® (loteprednol etabonate ophthalmic suspension), and various generic cyclosporine formulations (e.g., Restasis®, Cequa®). It also faces competition from numerous over-the-counter products.
• Allergic Conjunctivitis (AC): The AC market features various antihistamine eye drops and mast cell stabilizers.
• Aldeyra's Differentiator: Reproxalap's novel mechanism of action, as an 'aldehyde trap,' aims to offer a differentiated treatment by targeting a distinct inflammatory pathway. This approach could potentially provide benefits over existing therapies. Aldeyra believes this unique mechanism could offer a competitive advantage in efficacy and/or safety profile.

7. Future Outlook & Strategy

Aldeyra's future depends heavily on the successful regulatory and commercial advancement of reproxalap. Its core strategy remains to secure FDA approval for reproxalap in DED and AC, explore reproxalap's potential in other immune-mediated inflammatory conditions, and evaluate strategic partnerships for commercialization and further development.

• Near-Term (2026): Aldeyra anticipates resubmitting the New Drug Application (NDA) for reproxalap in DED in the second quarter of 2026. If accepted, this could lead to a potential PDUFA (Prescription Drug User Fee Act) date in the fourth quarter of 2026 – the target date for the FDA to complete its review. Aldeyra also plans to continue discussions with regulatory bodies regarding reproxalap for AC, aiming for a potential NDA filing in the future.
• Mid-Term: Pending FDA approval, Aldeyra aims to prepare for reproxalap's potential commercial launch in DED and advance its AC program towards a potential NDA filing. This includes building commercial capabilities and market access strategies.
• Long-Term: Aldeyra plans to continue leveraging its 'aldehyde trap' platform to identify and develop new drug candidates for a broader range of inflammatory diseases, expanding its pipeline beyond reproxalap. This includes exploring strategic collaborations to maximize the platform's potential.

8. Market Trends & Regulatory Environment

• Market Trends: The markets for ocular surface diseases, particularly dry eye disease, are growing due to an aging population, increased screen time, and environmental factors. Continuous demand exists for innovative and more effective treatments with favorable safety profiles. Aldeyra monitors these trends to effectively position reproxalap.
• Regulatory Environment: The evolving regulatory landscape, especially the FDA's requirements for ophthalmic drug development and approval, remains critical. Aldeyra actively monitors and adapts to these changes to navigate its drug candidates to market. Global economic and political stability also represent ongoing considerations for its operations and market access, potentially impacting clinical trial conduct, supply chains, and commercialization efforts.